Boston Scientific Announces 1000th European Patient Using LATITUDE(R) Patient Management System

Value of the Service Recognized by Patients and Physicians

PARIS, March 15, 2010 - Boston Scientific Corporation (NYSE: BSX) today announced that
it has reached the milestone of 1000 European patients using its LATITUDE(R)
Patient Management System. The LATITUDE system remotely monitors patients
with implantable cardiac devices, gathering information on both the device
and a patient's heart health status. The system can also transmit relevant
event notifications between scheduled hospital visits directly to a patient's
physician.

One of the patients using the system, Gritt Liebing, age 44
years of Darmstadt, Germany explained, "The LATITUDE system is brilliant. On
a practical level I do not need to call or visit the hospital as much, which
means I have more time for my normal life and my sports activities. Also my
family and I have the added reassurance and peace of mind that the system
will alert my doctor if any problems are detected. I would not want to go
back to the way it was before I used the system."

"I am really impressed with the LATITUDE system and service,"
said Dr. Haran Burri of Hôpitaux Universitaires of Geneva, Switzerland. "With
LATITUDE, I can choose to customize and receive information that enables me
to optimize patient treatment. I also value and appreciate the support I
receive from Boston Scientific, from helping train my staff to answering
questions through their dedicated support center."

LATITUDE is the only cardiac patient monitoring system that
can be associated with a wireless weight scale and blood pressure monitor,
thus enabling compliance with European Society of Cardiology Class 1
recommendations on management of heart failure patients.

"This progress demonstrates that the benefits of our LATITUDE
system are recognised and valued by both physicians and patients," said Fred
Hrkac, President of Europe, Middle East and Africa (EMEA) for Boston
Scientific. "This is another exciting milestone for our Company, spanning
from the first human implant of the ICD 30 years ago to manufacturing the
smallest, thinnest high-energy devices today. We expect continued success for
the LATITUDE system as the advantages of remote monitoring technology provide
a significant opportunity to further improve patient care."

The international version of the LATITUDE system is compatible
with the Company's wireless TELIGEN(R) implantable cardioverter defibrillator
(ICD) and COGNIS(R) cardiac resynchronization therapy defibrillator (CRT-D),
the world's smallest and thinnest high-energy devices.

A video testimony of Gritt Liebing can be viewed at

www.bostonscientific.com/templatedata/imports/multimedia/CRM/LATITUDE_Liebing_Intl.wmv

(Due to the length of this URL, it may be necessary to copy and paste
this hyperlink into your Internet browser's URL address field. Remove the
space if one exists.)

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:
www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within
the meaning of Section 21E of the Securities Exchange Act of 1934.
Forward-looking statements may be identified by words like "anticipate,"
"expect," "project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs, assumptions
and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements regarding
clinical trials, scientific activities, product performance, competitive
offerings and growth investment. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual results
could vary materially from the expectations and projections expressed or
implied by our forward-looking statements. These factors, in some cases, have
affected and in the future (together with other factors) could affect our
ability to implement our business strategy and may cause actual results to
differ materially from those contemplated by the statements expressed in this
press release. As a result, readers are cautioned not to place undue reliance
on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends; intellectual
property; litigation; financial market conditions; and, future business
decisions made by us and our competitors. All of these factors are difficult
or impossible to predict accurately and many of them are beyond our control.
For a further list and description of these and other important risks and
uncertainties that may affect our future operations, see Part I, Item 1A-
Risk Factors in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II, Item 1A -
Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file
thereafter. We disclaim any intention or obligation to publicly update or
revise any forward-looking statements to reflect any change in our
expectations or in events, conditions, or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.

Contact: Geraldine Varoqui, Director International Public Relation, Tel: +49-2102-489-461, Mob: +49-170-782-85-58, varoquig at bsci.com